| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699516 | Clinical Oncology | 2013 | 7 Pages |
Abstract
PDR schedules have been calculated to correspond with our established LDR treatments in terms of EQD2 dose to the target. There is a theoretical improvement in the therapeutic ratio due to a reduction in the calculated EQD2 to organs at risk.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
S. Baker, A. Pooler, J. Hendry, S. Davidson,